Avience Biomedicals
· SME · NSE
Price Band
₹196–208
Lot Size
600 shares
Issue Size
₹30 Cr
Min. Investment
₹2,49,600
Grey Market Premium
Last unofficial quote before listing
No grey-market quote was reported for this issue before it listed.
Subscription Status
Category-wise subscription figures aren't available for this issue.
Avience BiomedicalsIPO: Overview & Key Facts
Avience Biomedicals IPO is an SME issue that listed on NSE on 25 June 2026. The price band is ₹196–₹208 per equity share, with a market lot of 600 shares. The total issue size is ₹30 Cr. At the upper price band, the minimum application for an individual investor is 2 lots (1,200 shares), amounting to ₹2,49,600 — SME issues require individual investors to bid for at least two lots.
Avience Biomedicals IPO GMP & Listing
No grey market premium was reported for Avience Biomedicals IPO before it listed. The shares opened at ₹395.2 on listing day, 90% above the issue price of ₹208. An absent quote is not in itself a negative signal; SME issues in particular see little off-market trading. Read our complete guide to IPO GMP mechanics.
Avience Biomedicals IPO Allotment & Listing
The registrar for this issue is Skyline Financial Services Pvt. Ltd.; the basis of allotment was finalised on 23 June 2026 and the shares listed on 25 June 2026. You can check your allotment status on our IPO Allotment Checker using your PAN or application number.
Listing Performance
Issue Price
₹208
Listed At
₹395.2
Current Price
₹414.95
Issue Objectives
- Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
- Funding the working capital requirements of the Company
- General Corporate Purposes
- Public Issue Expenses
Reservation
| Category | Shares Offered | % |
|---|---|---|
| QIB | 6,83,400 | 49.83% |
| − Anchor Investor | 4,09,800 | 0% |
| − QIB (Ex. Anchor) | 2,73,600 | 0% |
| NII (HNI) | 2,07,000 | 15.09% |
| − bNII > ₹10L | 1,38,000 | 0% |
| − sNII < ₹10L | 69,000 | 0% |
| Retail | 4,81,200 | 35.08% |
| Market Maker | 82,200 | 0% |
- QIB49.8%
- − Anchor Investor0.0%
- − QIB (Ex. Anchor)0.0%
- NII (HNI)15.1%
- − bNII > ₹10L0.0%
- − sNII < ₹10L0.0%
- Retail35.1%
- Market Maker0.0%
Market Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 1200 | ₹2,49,600 |
| Individual investors (IND) (Max) | 2 | 1200 | ₹2,49,600 |
| S-HNI (Min) | 3 | 1800 | ₹3,74,400 |
| S-HNI (Max) | 8 | 4800 | ₹9,98,400 |
| B-HNI (Min) | 9 | 5400 | ₹11,23,200 |
Financials (₹ Cr)
Valuations
EPS (Pre IPO)
17.94
EPS (Post IPO)
12.56
ROE
22.38%
P/E (Pre IPO)
11.59
P/E (Post IPO)
16.56
Market Cap
₹83.85 Cr.
Contact Details
Avience Biomedicals Ltd. Address
- 1100581800-12-04
- info@avienbio.com
- https://avienbio.com/
Registrar Contact Details
Skyline Financial Services Pvt. Ltd.
- +91 11 4045 0193
- ipo@skylinerta.com
- https://skylinerta.com
- D-153/A, 1st Floor, Okhla Industrial Area Phase-I, New Delhi – 110020
Frequently Asked Questions
Key Dates
- Open Date
- 18 Jun 2026
- Close Date
- 22 Jun 2026
- Basis of Allotment
- 23 Jun 2026
- Listing Date
- 25 Jun 2026
Issue Details
- Registrar
- Skyline Financial
- Exchange
- NSE